Despite a Complete Response Letter for its epinephrine film Anaphylm, Aquestive Therapeutics receives a vote of confidence from Leerink Partners. The firm highlights a 'silver lining,' noting the FDA's requests appear addressable without major new studies, setting a defined, though delayed, route to potential U.S. approval.
Palantir Technologies Inc. (PLTR) surged in pre-market trading after delivering a fourth-quarter earnings beat and issuing a full-year revenue forecast that dramatically exceeded Wall Street expectations, powered by explosive growth in its U.S. commercial business.
Fireblocks, a leading digital asset infrastructure provider, has integrated the Canton Network into its platform, offering financial institutions a privacy-focused, regulated environment for tokenization and settlement. The move signals growing institutional demand for compliant blockchain infrastructure.
Becton Dickinson (BD) sees its price target raised by Piper Sandler as the medtech giant prepares to overhaul its financial reporting structure and invests heavily in prefillable syringe production to meet booming demand for GLP-1 and biologic drugs.
French cybercrime units, supported by Europol, conducted a search of X's Paris offices Tuesday as part of a criminal investigation into whether its Grok AI system was used to create and disseminate illegal material, including child sexual abuse imagery and Holocaust denial content.
The number of British homes valued at over £1 million has fallen by nearly 10% since 2022, new data reveals, though select commuter towns are seeing a surge in high-value sales as the return-to-office shift reshapes housing priorities.
Despite a robust 45% surge in earnings per share, Lonza Group AG (VTX:LONN) shareholders have seen their investment decline by 11% over the past year, starkly underperforming the broader Swiss market. This divergence underscores how investor sentiment and future expectations can overshadow even solid current financial performance.
Aquestive Therapeutics faces a regulatory delay for its sublingual epinephrine film, Anaphylm, after the FDA raised concerns primarily about its packaging and labeling. The company views the issues as solvable and is moving forward with redesigns and new studies, aiming for a 2026 resubmission while advancing parallel filings abroad.
As healthcare and living expenses climb, experts outline potential administrative and legislative avenues that could impact retiree finances in the coming years, from Medicare reform to tax adjustments.
A J.P. Morgan report reveals a growing funding chasm in biopharma, as venture capital flocks to de-risked late-stage companies, forcing early-stage innovators to pivot toward licensing deals and strategic partnerships for survival.
Elon Musk and former X CEO Linda Yaccarino have been summoned for questioning in Paris, as French cybercrime units search the platform's local offices. The probe focuses on content algorithms, data practices, and the controversial 'Grok' AI's ability to generate non-consensual explicit imagery.
For those without children, retirement planning offers unique freedoms but demands heightened focus on long-term care and estate logistics. Experts warn that skipping these critical steps can lead to significant financial and legal pitfalls.
The AI-native platform for audit and advisory firms closes a Series C round led by Goldman Sachs, aiming to scale its model of human-AI collaboration in a $700 million valuation milestone.
While Corning's stock has more than doubled in the past year, dramatically outpacing the broader market, analyst sentiment reveals a nuanced, slightly tempered optimism about its future trajectory.
Tron founder Justin Sun sees AI as crypto's next frontier but argues the sector lacks a defining consumer application to ignite sustained growth, leaving established use cases like payments in the driver's seat.
While major indices waver, a select group of undervalued small-cap companies is attracting attention from those who know them best—their own executives. We examine three firms where recent insider buying hints at underlying value, from UK pubs to Canadian tech and U.S. manufactured housing.
Sharp Corporation's shares have tumbled over 23% in the past year, lagging behind industry peers. A deep dive into valuation metrics reveals a complex picture: while a discounted cash flow model suggests the stock is fairly priced, its depressed P/E ratio signals potential undervaluation. As the iconic Japanese electronics maker navigates a challenging market, investors are divided on whether this represents a buying opportunity.
As market concentration reaches historic levels, investors are searching for sustainable growth beyond the usual megacap suspects. We analyze Appian, JFrog, and Lam Research, separating potential from peril in today's volatile tech landscape.
Following strong Q3 FY2026 results, data protection specialist Commvault is deploying capital returns and a new sovereign-cloud strategy to reinforce its market position, even as investors grapple with valuation concerns in a shifting tech landscape.
ARS Pharmaceuticals secures a key European regulatory nod to expand its needle-free anaphylaxis spray, EURneffy, to younger children. While this bolsters the company's franchise, analysts highlight that core challenges of cash burn and market adoption persist, keeping investor sentiment mixed.
